Reuters logo
BRIEF-Aclaris Therapeutics submits NDA for its treatment for seborrheic keratosis
February 27, 2017 / 1:32 PM / 7 months ago

BRIEF-Aclaris Therapeutics submits NDA for its treatment for seborrheic keratosis

Feb 27 (Reuters) - Aclaris Therapeutics Inc

* Aclaris Therapeutics Inc - submitted a new drug application to U.S. FDA for A-101 40 percent topical solution as a treatment for seborrheic keratosis

* Aclaris Therapeutics Inc - also plans to submit a marketing authorization application for A-101 in European Union in mid-2017 Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below